Evidence map›Paper›PMID 29113426›Full record

ArticleOncotarget2017

Activating mutation of

Xiaoling Fu, Weixin Niu, Ji Li, Amber J Kiliti, Hikmat A Al-Ahmadie, Gopa Iyer, Sizhi Paul Gao, Qi Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Genetic aberrations and molecular biology of cardiac sarcoma.Therapeutic advances in medical oncology · 2020
    Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Xiaoling FuDepartment of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China.
Weixin NiuDepartment of Surgery, Zhongshan Hospital of Fudan University, Shanghai, P.R. China.
Ji LiDepartment of Pancreatic Surgery, Huashan Hospital, Fudan University and Shanghai Medical School, Shanghai, P.R. China.
Amber J KilitiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Hikmat A Al-AhmadieDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Gopa IyerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sizhi Paul GaoHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Qi LiDepartment of Medical Oncology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, P.R. China.
Memorial Sloan Kettering Cancer Center · USFudan University · CNCornell University · USShanghai University of Traditional Chinese Medicine · CNShuguang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiac sarcoma is a rare malignant tumor with undefined genetic mutations and no targeted therapy. Here in one rare case of undifferentiated cardiac intimal sarcoma (IS), a next-generation sequencing based assay, MSK-IMPACT (Memorial Sloan Kettering - Integrated Mutation Profiling of Actionable Cancer Targets), identified a somatic, activating mutation in

Indexed as

cardiac sarcomaintimal sarcomamemorial sloan kettering-integrated mutation profiling of actionable cancer targetsPDGFRAPDGFRB

Identifiers

PMID29113426
PMCPMC5655321
OpenAlexW2753231697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.